Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.

Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU 3rd, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA; Children's Oncology Group.

Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566.

2.

Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.

Meyers PA, Chou AJ.

Adv Exp Med Biol. 2014;804:307-21. doi: 10.1007/978-3-319-04843-7_17. Review.

PMID:
24924182
3.

Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.

Mori K, Ando K, Heymann D.

Expert Rev Anticancer Ther. 2008 Feb;8(2):151-9. doi: 10.1586/14737140.8.2.151. Review.

PMID:
18279055
4.
5.

Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.

Kleinerman ES.

Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38. Review.

PMID:
7490249
6.

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.

Nardin A, Lefebvre ML, Labroquère K, Faure O, Abastado JP.

Curr Cancer Drug Targets. 2006 Mar;6(2):123-33. Review.

PMID:
16529542
7.

Mifamurtide for the treatment of nonmetastatic osteosarcoma.

Ando K, Mori K, Corradini N, Redini F, Heymann D.

Expert Opin Pharmacother. 2011 Feb;12(2):285-92. doi: 10.1517/14656566.2011.543129. Review.

8.

Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.

Kleinerman ES, Maeda M, Jaffe N.

Cancer Treat Res. 1993;62:101-7. Review.

PMID:
8096724
9.

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.

Meyers PA.

Expert Rev Anticancer Ther. 2009 Aug;9(8):1035-49. doi: 10.1586/era.09.69. Review.

PMID:
19671023
10.

Liposomal MTP-PE: a promising new biologic response modifier.

Gano JB, Kleinerman ES.

Oncol Nurs Forum. 1995 Jun;22(5):809-16. Review.

PMID:
7675688
11.

Liposomal MTP-PE.

Gano JB, Kleinerman ES.

J Pediatr Oncol Nurs. 1994 Oct;11(4):161-3. Review. No abstract available.

PMID:
7946146
12.

[L-MTP-PE--a potential antineoplastic agent].

Dzierzbicka K, Gozdowska M, Kołodziejczyk AM.

Postepy Hig Med Dosw. 1997;51(2):227-36. Review. Polish.

PMID:
9235567
14.
15.

Mifamurtide in osteosarcoma--a practical review.

Anderson PM, Tomaras M, McConnell K.

Drugs Today (Barc). 2010 May;46(5):327-37. doi: 10.1358/dot.2010.46.5.1500076. Review.

PMID:
20517534
16.

Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.

Sun L, Li Y, Li H, Zhang J, Li B, Ye Z.

Clin Ther. 2014 Apr 1;36(4):567-78. doi: 10.1016/j.clinthera.2014.02.018. Epub 2014 Mar 14. Review.

PMID:
24636527
17.

Mifamurtide: a review of its use in the treatment of osteosarcoma.

Frampton JE.

Paediatr Drugs. 2010 Jun;12(3):141-53. doi: 10.2165/11204910-000000000-00000. Review.

PMID:
20481644
18.

Systemic therapy for osteosarcoma and Ewing sarcoma.

Meyers PA.

Am Soc Clin Oncol Educ Book. 2015:e644-7. doi: 10.14694/EdBook_AM.2015.35.e644. Review.

19.

Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis.

Fan XL, Cai GP, Zhu LL, Ding GM.

Drug Des Devel Ther. 2015 Nov 4;9:5925-32. doi: 10.2147/DDDT.S91217. eCollection 2015. Review.

20.

Children's Oncology Group's 2013 blueprint for research: bone tumors.

Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N; COG Bone Tumor Committee.

Pediatr Blood Cancer. 2013 Jun;60(6):1009-15. doi: 10.1002/pbc.24429. Epub 2012 Dec 19. Review.

Supplemental Content

Support Center